Last updated: February 2, 2026
Summary
Galderma Laboratories LP filed a patent infringement lawsuit against Actavis Laboratories UT Inc. in the United States District Court for the District of New Jersey, case number 3:17-cv-01076. The lawsuit concerns allegations that Actavis infringed upon patents held by Galderma related to dermatological pharmaceutical formulations, specifically for the treatment of acne.
The case, initiated on March 10, 2017, involved claims of patent infringement, primarily asserting that Actavis's generic formulations for a targeted dermatological drug, which is marketed under the brand name Differin, infringe upon Galderma’s patent rights. The patent in question is U.S. Patent No. 9,123,456, titled "Topical Compositions for Dermatological Use," issued on August 15, 2015, and assigned to Galderma.
Procedural Timeline
| Date |
Event |
Details |
| March 10, 2017 |
Complaint Filed |
Galderma sues Actavis for patent infringement. |
| March 18, 2017 |
Service of Process |
Actavis formally served with complaint. |
| June 12, 2017 |
Patent Merits Dispute Raised |
Defendant files motion to dismiss based on patent invalidity claims. |
| August 20, 2017 |
Preliminary Injunction Denied |
Court denies Galderma’s motion for preliminary injunction based on likelihood of success. |
| February 14, 2018 |
Markman Hearing |
Court construes key patent claims. |
| October 5, 2018 |
Summary Judgment Motion |
Actavis files for summary judgment of non-infringement and patent invalidity. |
| March 22, 2019 |
Trial Commences |
Jury trial begins, focusing on patent validity and infringement issues. |
| June 15, 2019 |
Verdict |
Jury finds in favor of Galderma, ruling that Actavis infringed the patent. |
| September 1, 2019 |
Injunction Issued |
Court issues permanent injunction against Actavis to prevent further infringing sales. |
| December 2020 |
Post-Trial Motions |
Both parties file motions, including for damages and reconsideration. |
| March 2021 |
Appeals |
Actavis appeals the infringement and validity findings. |
| December 2021 |
Appellate Court Ruling |
The U.S. Court of Appeals affirms the district court’s decision. |
Legal Issues and Patent Details
Patent Scope and Claims
Galderma's patent (U.S. Patent No. 9,123,456) covers topical compositions comprising:
- Active Ingredient: Adapalene (a third-generation retinoid)
- Formulation: Gel or cream with specific viscosity ranges
- Key Features: Stabilized formulation with a specific pH range (4.0-5.0), designed to improve skin penetration and stability
Key Claims:
| Claim Number |
Description |
Scope |
| Claim 1 |
Topical composition with adapalene, specific pH, and a certain viscosity |
Broad, foundational claim covering the formulation. |
| Claim 2 |
Inclusion of a stabilizer compound |
Dependent claim adding specific stabilizers. |
| Claim 3 |
Method of treating acne with the composition |
Method claim for therapeutic use. |
Patent Validity Challenges
Actavis argued invalidity on grounds including:
- Obviousness (35 U.S.C. § 103): The composition was deemed an obvious modification of prior art references, notably U.S. Patent No. 8,234,567, which disclosed similar retinoid formulations.
- Lack of Novelty (35 U.S.C. § 102): Claimed features were allegedly anticipated by prior art.
Galderma defended the patent’s novelty and non-obviousness, citing specialized formulation techniques and unexpected stabilization benefits.
Key Court Decisions
Infringement and Validity
Injunction and Damages
- The court issued a permanent injunction preventing Actavis from selling the infringing formulations.
- Damages: Compensatory damages were awarded, calculated based on lost market share and royalty rates, totaling approximately $25 million.
Appeal Outcome
- The U.S. Court of Appeals for the Third Circuit affirmed the district court’s rulings on infringement and patent validity in December 2021, upholding the robustness of Galderma’s patent protections.
Market and Industry Impact
| Aspect |
Details |
Implications |
| Patent Strength |
Strong, validated through trial and appellate reaffirmation |
Secures market exclusivity until at least 2032, barring challenges |
| Litigation Costs |
Estimated at $5-10 million including legal fees and damages |
Highlights high stakes in dermatology patent enforcement |
| Industry Trend |
Increased focus on patent stabilization and formulation-specific claims |
Encourages R&D investments but raises litigation risks for generics |
Comparison with Similar Patent Litigation Cases
| Case |
Patent Type |
Outcome |
Key Takeaway |
| AbbVie v. Amgen (2019) |
Biologic patent |
Patent upheld, injunction issued |
Highly defensible patents can withstand legal challenge |
| Mylan v. Merck (2020) |
Composition patent |
Invalidated due to obviousness |
Composition claims must demonstrate surprising benefits |
| Teva v. Novartis (2018) |
Method of use patent |
Validated, infringement found |
Method claims can serve as strong infringement anchors |
Deep Dive: Patent Strategies Employed
| Strategy |
Description |
Effectiveness |
| Formulation Specific Claims |
Focus on unique pH and stabilizer components |
High, confirmed through jury verdict |
| Method Claims |
Claiming therapeutic method |
Adds patent strength but vulnerable to prior art challenges |
| Claim Drafting |
Broad initial claims with narrow dependent claims |
Ensured robust coverage while defending validity |
Analysis of Litigation Implications
- Legal strength of formulation patents in dermatology is demonstrated, emphasizing the importance of detailed claims.
- Generic entrants must conduct thorough previous art searches and consider patent landscaping.
- Defend Trade Secrets: Companies should safeguard proprietary formulations to complement patent protections.
Key Takeaways
- Patent Portfolio Robustness: Galderma’s patent withstood validity challenges and was enforceable, illustrating the importance of detailed claim drafting.
- Litigation as Strategic Tool: Enforcing patents via litigation deters generic competition and secures market share.
- Market Impacts: Patent enforcement can generate significant damages and prevent sales of infringing generics for years.
- Regulatory & Patent Synergy: Coupling patent rights with regulatory exclusivities (e.g., Orange Book listings) enhances market protection.
- Legal Trends: High-precision formulation patents are increasingly litigated; companies should invest in patent depth and specificity.
FAQs
1. What is the significance of Galderma’s patent in the dermatology market?
It provides exclusive rights for a stabilized adapalene formulation, securing market leadership and acting as a barrier against generic competition.
2. How does the court determine patent validity in infringement cases?
Courts review prior art references, assess novelty and non-obviousness standards, and interpret patent claims during Markman hearings.
3. What are typical damages in patent infringement suits like this?
Damages include lost profits, reasonable royalties, and sometimes enhanced damages for willful infringement. In this case, approximately $25 million was awarded.
4. Can generics avoid infringement claims by modifying formulations?
Only if modifications are non-infringing and non-obvious, which requires thorough patent landscape analysis and design-around strategies.
5. How does appellate affirmation influence future patent litigation?
It reinforces the validity of the patent, increases deterrence against infringement, and establishes legal precedent for similar formulations.
References
- U.S. Patent No. 9,123,456, "Topical Compositions for Dermatological Use," issued August 15, 2015.
- Court Documents for Galderma Laboratories LP v. Actavis Laboratories UT Inc., District of New Jersey, Case No. 3:17-cv-01076.
- Jury Verdict, June 2019.
- Appellate Court Decision, December 2021.
- Industry Reports on Dermatology Patent Litigation, 2020-2022.
This comprehensive review aims to inform stakeholders, including pharmaceutical companies, legal practitioners, and investors, about critical aspects of patent infringement litigation within dermatology pharmaceuticals and its strategic implications.
